CRISPR Therapeutics AG (CRSP)
| Market Cap | 4.67B |
| Revenue (ttm) | 371.21M |
| Net Income (ttm) | -153.61M |
| Shares Out | 84.88M |
| EPS (ttm) | -1.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,761,377 |
| Open | 56.16 |
| Previous Close | 56.16 |
| Day's Range | 54.28 - 57.50 |
| 52-Week Range | 37.55 - 91.10 |
| Beta | 1.74 |
| Analysts | Buy |
| Price Target | 81.44 (+47.94%) |
| Earnings Date | May 6, 2024 |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product cand... [Read more]
Financial Performance
In 2023, CRSP's revenue was $371.21 million, an increase of 30885.48% compared to the previous year's $1.20 million. Losses were -$153.61 million, -76.37% less than in 2022.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is $81.44, which is an increase of 47.94% from the latest price.
News
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
ZUG, Switzerland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...
Final Trade: HPQ, RSG, GM, CRSP
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed
Samarth Kulkarni, Crispr Therapeutics CEO, joins 'Power Lunch' to discuss the hurdles to getting rare disease drugs through regulation, what consumers can look forward to in gene editing, and much mor...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain —
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabete...
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
— Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment —
FDA Approves New CRISPR Gene-Editing Treatment
The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusio...
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (N...
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 1...
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
Crispr Therapeutics chief medical officer is resigning
Crispr Therapeutics CRSP, +8.84% on Tuesday said that Phuong Khanh Morrow was resigning as the gene-editing company's chief medical officer, a move that takes hold on Jan. 26. The resignation was “not...
Final Trades: PBR, DELL, FSLR & CRSP
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
CRISPR Therapeutics CEO talks winning FDA approval for sickle cell anemia treatment
Samarth Kulkarni, CRISPR Therapeutics CEO, joins 'Closing Bell Overtime' to talk winning FDA approval in the U.S. for sickle cell treatment in partnership with Vertex.
Sickle cell gene editing faces market hurdles: Analyst
"The FDA approved a gene editing treatment for sickle cell disease to alleviate severe, recurrent pain crises. Casgevy, developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), is a ...
The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person
The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.
Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US
Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced Friday that the Food and Drug Administration (FDA) gave them approval for use of the first-ever gene-editing therapy using CRISPR...
FDA Approves First Crispr Treatment for Sickle Cell Disease
A gene-editing therapy for sickle cell disease was approved by US regulators, a milestone for the DNA-modifying technology Crispr. Crispr Co-Inventor, 2020 Nobel Prize winner in chemistry, and Innovat...
Patients describe Casgevy gene-editing treatment as a cure, says Vertex CEO Reshma Kewalramani
Reshma Kewalramani, CEO of Vertex Pharmaceuticals, and CNBC's Angelica Peebles join 'Power Lunch' to discuss the latest FDA gene-editing treatment approval, drug pricing, and more.
Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln
Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) h...
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
Crispr Therapeutics AG CRSP, -5.37% and Vertex Pharmaceuticals Inc. VRTX, -1.25% on Friday got U.S. regulatory approval for a treatment for sickle-cell disease based on the transformative gene-editing...